Thank you for visiting the VeriPsych website and for your interest in VeriPsych, the first blood-based diagnostic aid for schizophrenia.

We have temporarily suspended offering the VeriPsych test in an effort to improve its utility. In 2010, we conducted a beta launch confirming that the test worked as intended; however, in close collaboration with our medical and scientific partners, we collectively determined that the product needed further refinement to better fit the needs of patients and healthcare providers. Accordingly, we have shifted our focus onto the development of new transformative molecular diagnostic tools that address bi-polar disorder and major depression, in addition to schizophrenia. We are extremely excited by the progress made in bringing these diagnostic products to physicians and, most importantly, to the patients that can benefit from them. Unfortunately, there is currently no timeline for the availability of these new products in the United States or any other markets.

If you would like to receive information about our next generation of tests and their availability, please enter your email below. We will use this email distribution to release updates and news about the development of these new tests.

Thank You.

For media inquiries or other questions about VeriPsych please contact

Christopher E. Martin
Communications Director
Myriad RBM, Inc.
Direct: (512) 275-2623
Cell: (512) 627-9058